Tasly signed a contract with Huawei Cloud to build a large model of traditional Chinese medicine

On October 20, Tasly Pharmaceutical Group and Huawei Cloud Computing Technology Co., Ltd. signed a cooperation agreement. The two parties will combine traditional Chinese medicine characteristic data and the basic capabilities of the Pangu large model to build a large model of traditional Chinese medicine research and development, and further create a series of scenario applications. Leading AI-driven business innovation. This signing is an important continuation of the past cooperation explorations between the two parties, and marks that the cooperation between the two parties has further deepened and become more practical.

It is reported that Tasly insists on using modern technology to explain the multi-component and multi-target connotation of traditional Chinese medicine, using intelligent manufacturing technology to solve the problem of batch-to-batch quality consistency of complex components of traditional Chinese medicine, and using evidence-based medicine based on real-world research to prove the efficacy of traditional Chinese medicine and create It has established a full-chain R&D system from source discovery, new drug creation, industrial transformation to international development, and established an internationally leading intelligent manufacturing system for traditional Chinese medicine with quality digitalization as the core. On the basis of specializing in modern Chinese medicine, Tasly combines theoretical knowledge of Chinese medicine and clinical human experience with digital technologies such as big data, cloud computing and artificial intelligence to continuously promote the development of “digital intelligent Chinese medicine”. The independently developed Xingdou Cloud The intelligent research and development platform for traditional Chinese medicine has accumulated a massive amount of data on traditional Chinese medicine characteristics.

Huawei Cloud Pangu Large Model adheres to the concept of “AI for Industries” and is committed to deepening the industry. It has currently launched large industry models and capability sets in finance, government affairs, medical care, manufacturing, mining, meteorology, railways and other fields, integrating knowledge in various industries. -How combines with large model capabilities to provide technical support and decision-making support to industry customers, helping organizations and enterprises better realize business intelligence.

In the medical field, Huawei Cloud has launched the Pangu Medical Model and the Pangu Drug Molecular Model based on the Pangu Model L0. Based on this cooperation, both parties will build a large vertical model in the field of traditional Chinese medicine by combining traditional Chinese medicine classics, literature, clinical data, modern research data on traditional Chinese medicine and natural products, etc. Use large models to accelerate the innovation and transformation of traditional Chinese medicine, solve research and development pain points such as sparse and discrete information on traditional Chinese medicine, and promote the inheritance of the treasure house of traditional Chinese medicine knowledge. Utilize the intelligent information mining capabilities of large models to deeply extract the theoretical connotations of traditional Chinese medicine formulas, medicinal ingredients, and molecular structures to achieve accurate characterization calculations of compound traditional Chinese medicines, facilitate the accurate mining of traditional Chinese medicine knowledge, form digital intelligent research on traditional Chinese medicine, and accelerate Innovate the entire process of R&D in the traditional Chinese medicine industry.

Based on Tasly’s deep industry experience and service resource advantages in the field of traditional Chinese medicine, and Huawei Cloud’s leading technology, platform and computing power in AI large models, we will work closely to develop innovative traditional Chinese medicines and jointly establish new standards for intelligent research on traditional Chinese medicines. , while adhering to an open and inclusive R&D model, will deepen cooperation with domestic research institutions and universities in the future, gradually form a traditional Chinese medicine inheritance and innovation mechanism integrating industry, academia, and research, and build a new paradigm of traditional Chinese medicine research and development. Both parties will achieve complementary advantages and win-win value. Jointly promote high-quality innovative development in the field of traditional Chinese medicine research and development, and jointly create a new chapter in the integration of traditional Chinese medicine and AI.

Yan Kaijing, Chairman of Tasly Pharmaceutical Group, and Su Jing, General Manager; Zhou Shuiping, Executive Director of Tasly Research Institute; Li Sirui, General Manager of Tasly Holdings Group Strategic Development Center; Shi Jianhua, General Manager of Tasly Digital Innovation Center; General Manager of Tasly International Gene Network Drug Innovation Center Manager Wang Wenjia, Vice President of Huawei Cloud Computing Technology Co., Ltd. Huang Jin, Director of Huawei Cloud EI Service Product Department You Peng, and General Manager of Huawei Cloud Tianjin Cloud Business Department Lin Zhiyong attended the signing ceremony.

Source link